CN101528747A - 3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法 - Google Patents

3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法 Download PDF

Info

Publication number
CN101528747A
CN101528747A CNA2007800390918A CN200780039091A CN101528747A CN 101528747 A CN101528747 A CN 101528747A CN A2007800390918 A CNA2007800390918 A CN A2007800390918A CN 200780039091 A CN200780039091 A CN 200780039091A CN 101528747 A CN101528747 A CN 101528747A
Authority
CN
China
Prior art keywords
compound
present
composition
acid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800390918A
Other languages
English (en)
Chinese (zh)
Inventor
罗杰·通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of CN101528747A publication Critical patent/CN101528747A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007800390918A 2006-10-20 2007-10-22 3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法 Pending CN101528747A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85323406P 2006-10-20 2006-10-20
US60/853,234 2006-10-20

Publications (1)

Publication Number Publication Date
CN101528747A true CN101528747A (zh) 2009-09-09

Family

ID=39492926

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800390918A Pending CN101528747A (zh) 2006-10-20 2007-10-22 3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法

Country Status (9)

Country Link
US (1) US8552008B2 (enExample)
EP (1) EP2089392A4 (enExample)
JP (1) JP2010507593A (enExample)
KR (1) KR20090091138A (enExample)
CN (1) CN101528747A (enExample)
AU (1) AU2007329728A1 (enExample)
CA (1) CA2664940A1 (enExample)
MX (1) MX2009003941A (enExample)
WO (1) WO2008070313A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090270425A1 (en) * 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090197899A1 (en) * 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
EP4010338A1 (en) 2019-08-06 2022-06-15 Incyte Corporation Solid forms of an hpk1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BRPI0615972A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20090270425A1 (en) 2006-10-20 2009-10-29 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090197899A1 (en) 2006-10-20 2009-08-06 Concert Pharmaceuticals Inc. 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
US20080280927A1 (en) 2006-10-20 2008-11-13 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use

Also Published As

Publication number Publication date
AU2007329728A1 (en) 2008-06-12
WO2008070313A3 (en) 2008-11-20
EP2089392A4 (en) 2010-05-05
JP2010507593A (ja) 2010-03-11
MX2009003941A (es) 2009-04-24
KR20090091138A (ko) 2009-08-26
CA2664940A1 (en) 2008-06-12
WO2008070313A2 (en) 2008-06-12
EP2089392A2 (en) 2009-08-19
US20080188496A1 (en) 2008-08-07
US8552008B2 (en) 2013-10-08

Similar Documents

Publication Publication Date Title
CN101528747A (zh) 3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法
US10842792B2 (en) Deuterated baricitinib
ES2425183T3 (es) Derivados de oxazolidinonas sustituidas
RU2695650C2 (ru) Ингибиторы аргиназы и способы их применения
US20010047000A1 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
CN1261791A (zh) 诊断或治疗用途的靶向脂质体构建物
CN101259131A (zh) 用于细胞增殖性障碍的二氢吲哚酮与化疗剂的联合给药
JPH02108636A (ja) 抗腫瘍性組合せ製剤
CN101385738A (zh) 包括给予A1腺苷激动剂以及β受体阻滞剂、钙通道阻滞剂、或强心苷的治疗心律失常的方法
ES2672468T3 (es) Momelotinib deuterado
JP7733058B2 (ja) Ｄ－セリンの重水素化類似体およびその使用
JP2017510561A (ja) ヘテロ環式化合物
US20110212944A1 (en) 2-oxo-1-pyrrolidine derivatives
UA127738C2 (uk) Проліки дантролену і способи їх застосування
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのｐｐｍｐ
CN1330309C (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
JP2025028945A (ja) ビスホスホネート連結化合物
CA1121727A (en) Process for producing detoxified pharmaceutical products containing a cytostatically active alkylating agent
JP2016512530A (ja) 重水素化されたパクリチニブ
JP2022524887A (ja) ヒストンデアセチラーゼ１０の新規の阻害剤
ES2694202T3 (es) Idebenona deuterada
EP4423099A1 (en) Novel anti-depressant and neuroplastic agents and therapeutic uses thereof
EA050051B1 (ru) Дейтерированные аналоги d-серина и их применение
MXPA98007808A (en) Use of olanzapine to treat the do

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090909